Hospital
Hca Health Services of Florida, INC.
Hca Health Services of Florida, INC. was paid $4.57M by Medicaid between Jan 2018 and Apr 2023, across 121 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoHCA HEALTH SERVICES OF FLORIDA, INC.
BRADENTON, FL 34209
BRADENTON, FL 34209
33aNPI1629023015assigned 05/23/2006
33bProvider typeRehabilitation Hospital Unit
28Total paid$4.57M
24GClaims221,613
24DCodes billed121
24AFirst – last monthJan 2018 – Apr 2023
Compared with peers
Next to other Rehabilitation Hospital Unit providers in Florida
Rank by total paid#10 of 11
Median peer was paid$15.92M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 19,833 | $379K | |
| 2019 | 51,745 | $699K | |
| 2020 | 37,274 | $544K | |
| 2021 | 49,086 | $1.11M | |
| 2022 | 53,324 | $1.51M | |
| 2023 | 10,351 | $328K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 14,506 | 12,983 | $982K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 7,299 | 2,583 | $528K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 12,334 | 10,150 | $488K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 8.2% | 5,623 | 1,326 | $373K |
| 70450 | Computed tomography, head or brain; without contrast material | 6.2% | 3,424 | 2,615 | $284K |
| 80053 | Comprehensive metabolic panel | 5.8% | 13,402 | 10,402 | $264K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.4% | 1,602 | 1,377 | $248K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.5% | 2,707 | 2,533 | $207K |
| G0378 | Hospital observation service, per hour | 3.3% | 5,026 | 1,559 | $149K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.2% | 1,294 | 1,069 | $144K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.9% | 1,381 | 1,265 | $131K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.6% | 254 | 215 | $75K |
109 more codes
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.6% | 2,124 | $71K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.0% | 870 | $46K |
| 87070 | <1% | 2,404 | $41K | |
| 73130 | <1% | 637 | $38K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,232 | $37K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 284 | $29K |
| 84702 | <1% | 4,517 | $22K | |
| 81001 | <1% | 5,746 | $21K | |
| 93976 | <1% | 295 | $21K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,604 | $21K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 555 | $21K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,734 | $19K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 747 | $18K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 476 | $17K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,935 | $17K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,310 | $17K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 753 | $15K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,630 | $15K |
| 97760 | <1% | 228 | $12K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 454 | $12K |
| 85027 | <1% | 16,380 | $12K | |
| A9270 | Non-covered item or service | <1% | 6,645 | $8K |
| 97163 | <1% | 180 | $8K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,304 | $8K |
| 73630 | <1% | 505 | $7K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 405 | $7K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,229 | $7K |
| 94729 | <1% | 88 | $7K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,821 | $6K |
| 93971 | <1% | 104 | $6K | |
| 73564 | <1% | 445 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,054 | $6K |
| 81003 | <1% | 1,877 | $6K | |
| 87040 | <1% | 1,541 | $5K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 773 | $4K |
| J3490 | Unclassified drugs | <1% | 210 | $4K |
| 73610 | <1% | 301 | $4K | |
| 81025 | <1% | 1,705 | $4K | |
| 85610 | <1% | 4,125 | $4K | |
| 86850 | <1% | 585 | $4K | |
| 76830 | Ultrasound, transvaginal | <1% | 279 | $3K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 332 | $3K |
| S0028 | Injection, famotidine, 20 mg | <1% | 436 | $3K |
| 97165 | <1% | 105 | $3K | |
| 86900 | <1% | 1,012 | $3K | |
| 85730 | <1% | 2,605 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 852 | $3K |
| 87077 | <1% | 690 | $3K | |
| 86901 | <1% | 1,117 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,045 | $2K |
| 84484 | <1% | 5,881 | $2K | |
| 73110 | <1% | 106 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,143 | $2K |
| 83735 | <1% | 4,202 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 689 | $2K |
| 93970 | <1% | 15 | $1K | |
| 85379 | <1% | 519 | $1K | |
| 94060 | <1% | 91 | $1K | |
| 96376 | <1% | 514 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 564 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 396 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 389 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,334 | $1K |
| 12001 | <1% | 16 | $984.96 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 888 | $935.44 |
| 73030 | <1% | 55 | $888.66 | |
| 73140 | <1% | 14 | $831.16 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 624 | $784.79 |
| 82565 | <1% | 201 | $706.66 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,009 | $683.24 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,928 | $679.94 |
| 87210 | <1% | 166 | $677.84 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,556 | $604.71 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 15 | $590.34 |
| 97763 | <1% | 14 | $545.35 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,105 | $466.73 |
| 83690 | <1% | 4,267 | $461.63 | |
| 87088 | <1% | 289 | $429.95 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 109 | $377.80 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 97 | $301.89 |
| 76801 | <1% | 48 | $294.95 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,030 | $217.22 |
| 83880 | <1% | 891 | $205.40 | |
| 80051 | <1% | 38 | $152.70 | |
| 83605 | <1% | 1,068 | $145.27 | |
| 87186 | <1% | 326 | $114.01 | |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | <1% | 270 | $96.34 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,881 | $81.97 |
| 84520 | <1% | 87 | $68.73 | |
| 87400 | <1% | 65 | $35.16 | |
| 94727 | <1% | 89 | $16.72 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 301 | $4.69 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,498 | $0.04 |
| 84100 | 0% | 101 | $0.00 | |
| 90715 | 0% | 76 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 60 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 115 | $0.00 |
| 74018 | 0% | 33 | $0.00 | |
| 86756 | 0% | 83 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 620 | $0.00 |
| 72170 | 0% | 15 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 70 | $0.00 |
| 82550 | 0% | 115 | $0.00 | |
| 87147 | 0% | 12 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 23 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 261 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 16 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 74 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, THOMAS (CFO)
Parent organizationHCA HEALTH SERVICES OF FLORIDA, INC.
| Provider | Location | Paid |
|---|---|---|
| Hca Health Services of Florida, INC. | Bradenton, FL | $673K |
| Town of Winchendon | Winchendon, MA | $617K |
| Worthington Center Management Co, INC | Belpre, OH | $294K |
| Town of Templeton | Baldwinville, MA | $187K |
| Kent County Homecare Associates | Middletown, DE | $121K |
| Heartland Chiropractic Clinic PC | Bellevue, NE | $31K |
| Thomas G. Smith, D.C., PLC | Warren, MI | $21K |
| Village of West Alexandria | West Alexandria, OH | $7K |
| Thomas J Smith MD PS INC | Seattle, WA | $1K |
| Thomas M Smith DDS PLC | Norton Shores, MI | $211.75 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.